Journal
REVUE NEUROLOGIQUE
Volume 177, Issue 8, Pages 890-907Publisher
MASSON EDITEUR
DOI: 10.1016/j.neurol.2020.11.001
Keywords
Chemotherapy; Neurotoxicity; Neurofilament light chain; Markers; Metabolomics
Categories
Funding
- Associazione Italiana Ricerca sul Cancro (AIRC) [18631]
Ask authors/readers for more resources
The increased survival of cancer patients has led to a growing concern over the long-term consequences of antineoplastic treatment, particularly chemotherapy-induced peripheral neuropathy (CIPN). Clinical and biochemical markers are crucial for defining the potential risk and resolution of CIPN, while metabolomics markers are being studied for more accurate indicators of peripheral nerve damage.
The increased survival of cancer patients has raised growing public health concern on associated long-term consequences of antineoplastic treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is a primarily sensory polyneuropathy, which may be accompanied by pain, autonomic disturbances, and motor deficit. About 70% of treated cancer patients might develop CIPN during or after the completion of chemotherapy, and in most of them such complication persists after six months from the treatment. The definition of the potential risk of development and resolution of CIPN according to a clinical and biochemical profile would be certainly fundamental to tailor chemotherapy regimen and dosage on individual susceptibility. In recent years, patient-reported and clinician-related tools along with quality of life instruments have been featured as primary outcomes in clinical setting and randomized trials. New studies on metabolomics markers are further pursuing accurate and easily accessible indicators of peripheral nerve damage. The aim of this review is to outline the strengths and pitfalls of current knowledge on CIPN, and to provide a framework for future potential developments of standardized protocols involving clinical and biochemical markers for CIPN assessment and monitoring. (C) 2021 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available